TMO — Thermo Fisher Scientific Inc

Is TMO overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Diagnostics & Research

Overbought As of August 19, 2026

Thermo Fisher Scientific Inc (TMO) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Diagnostics & Research) last closed at $589.04. The rating moved from Neutral to Overbought on August 11, 2026.

See all overbought Healthcare stocks →

AI analysis

Thermo Fisher Scientific is positioned to capture secular growth from biologics, CRO/CDMO demand and rising diagnostic procedures while benefiting from recurring consumables revenue and strong cash generation. Near-term upside is supported by sector rotation into growth names and AI/diagnostics readthroughs, but results could be volatile if pharma R&D spending softens, integration costs persist, or reimbursement/regulatory pressures intensify. Overall fundamentals and market position support steady mid-term upside, though monitoring customer capex trends, FX, and acquisition execution is critical.

Key factors

  • Market leadership across lab consumables, instruments, and services with high recurring consumables revenue
  • Direct beneficiary of a GLP-1/biologics and CRO/CDMO tailwind that should support instrument and service demand
  • Diversified end-markets (pharma, biotech, clinical diagnostics, academic, industrial) that smooth cyclical volatility
  • Strong historical free cash flow and balance-sheet capacity to fund M&A and R&D, supporting long-term growth
  • Exposure to diagnostic and AI-enabled procedure growth given increasing demand for oncology screening and lab services
  • Pricing power on consumables and scale advantages in global supply chain and distribution
  • Resilient fiscal profile that can tolerate near-term macro softness while capturing structural growth in biologics and diagnostics

Risks

  • Slower-than-expected R&D and capex spending by pharma/biotech customers could reduce instrument and service orders
  • Integration risks and elevated leverage from prior acquisitions could pressure margins if growth slows
  • Reimbursement, payer rationalization, and regulatory changes that affect diagnostics and clinical services
  • Geopolitical or supply-chain disruptions that raise costs or delay deliveries of critical instruments/components
  • Foreign-exchange headwinds given large international revenue mix
  • Increased competition from specialized CRO/CDMO players and emerging diagnostic/automation vendors
  • Valuation compression if market rotates away from growth names or if near-term results miss elevated expectations

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for TMO — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.